All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Rezafungin (Rezzayo) vs Ziconotide (Prialt)

An educational, source-based comparison of Rezafungin (Rezzayo) and Ziconotide (Prialt) — how each peptide works, what it's researched for, and what to know before going deeper.

Echinocandin · Antifungal
Rezafungin (Rezzayo)

Once-weekly echinocandin for candidemia and invasive candidiasis.

Mechanism

Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.

Research areas
  • Candidemia
  • Invasive candidiasis
Considerations
  • FDA-approved (2023).
  • Infusion reactions and photosensitivity reported.
Full Rezafungin (Rezzayo) profile →
N-type Calcium Channel Blocker · Analgesic
Ziconotide (Prialt)

Synthetic ω-conopeptide for severe chronic pain via intrathecal infusion.

Mechanism

Synthetic version of ω-conotoxin MVIIA from cone snail Conus magus; selectively blocks N-type voltage-gated calcium channels on primary afferent nerve terminals in the spinal dorsal horn, inhibiting nociceptive neurotransmitter release.

Research areas
  • Severe chronic pain refractory to systemic analgesics, intrathecal morphine
Considerations
  • FDA-approved.
  • Black-box warning for severe psychiatric and neurologic effects.
  • Contraindicated in history of psychosis.
Full Ziconotide (Prialt) profile →

Rezafungin (Rezzayo) vs Ziconotide (Prialt) — Key differences

  • Class: Rezafungin (Rezzayo) is classified as Echinocandin · Antifungal, while Ziconotide (Prialt) is N-type Calcium Channel Blocker · Analgesic.
  • Primary research focus: Rezafungin (Rezzayo)candidemia; Ziconotide (Prialt)severe chronic pain refractory to systemic analgesics, intrathecal morphine.
  • Tag: FDA-Approved · Antifungal vs FDA-Approved · Pain.

Related comparisons